You are what you eat

Deakin expert sets her sights on the food industry in 'The Conversation.'

IMPACT on RRR

Dr Olivia Dean chatted with Triple R Radio about trials of new treatments for depression.

Osteoporosis - don't shrug it off!

IMPACT researchers discover that many with osteoporosis don't know they have it.

Making the connection

Increased risk of bone fractures for those with psychiatric disorders.

Contact us
Email:

berkoffice@barwonhealth.org.au

Phone:

+61 4215 3320

Mail:

IMPACT Strategic Research Centre (Barwon Health)
Deakin University
School of Medicine
PO Box 281
Geelong Victoria 3220

Novel therapies

Biological psychiatry is at the forefront of understanding the underlying factors involved in psychiatric disorders. In the IMPACT SRC we focus on alternative targets to treat the symptoms of psychiatric disorders using a multitude of approaches ranging from basic science through to clinical trials. Our trials are designed to fill the gap that conventional therapies often leave between getting better and complete, functional recovery. We target alterations in oxidative biology, inflammation, neurogenesis and mitochondrial dysfunction, factors that are believed to be important in the pathology of many psychiatric illnesses.

The SRC currently has a register open to anyone who has a psychiatric disorder and would be interested in taking part in our studies. If you would like more information regarding the register please contact Dr Olivia Dean - (03) 4215 3300.

Additionally, we have several studies that are currently recruiting:

  • Mino UD trial
    This study is trialling minocycline as an add-on to usual treatment for depression. The study requires people to attend seven interviews over the course of 16-weeks. The study is currently recruiting and seeking both men and women aged 18 years or over to take part.
    Contact: Dr Olivia Dean 03 4215 3300 or mino@barwonhealth.org.au.

  • Mito NAC trial
    This trial involves N-acetyl cysteine, known as NAC, in combination with other nutraceutical agents as a potential new treatment for bipolar disorder. We are seeking volunteers for the trial who are over 18 years of age and have a diagnosis of bipolar disorder. The study requires people to attend seven interviews over the course of 20-weeks.
    Contact: Dr Alyna Turner 03 4215 3313 or email mitobd@barwonhealth.org.au

  • YoDA-A trial
    This trial involves rosuvastatin and aspirin as treatments for youth depression. Please note this study requires participants to be currently undergoing treatment at; Orygen Youth Health Clinical Program, Headspace Sunshine or Headspace Glenroy.

Deakin University acknowledges the traditional land owners of present campus sites.

23rd May 2014